DK0454783T3 - Sted-specifik in vivo aktivering af terapeutiske lægemidler - Google Patents

Sted-specifik in vivo aktivering af terapeutiske lægemidler

Info

Publication number
DK0454783T3
DK0454783T3 DK90902934.0T DK90902934T DK0454783T3 DK 0454783 T3 DK0454783 T3 DK 0454783T3 DK 90902934 T DK90902934 T DK 90902934T DK 0454783 T3 DK0454783 T3 DK 0454783T3
Authority
DK
Denmark
Prior art keywords
activator
prodrug
target tissue
site
targeting moiety
Prior art date
Application number
DK90902934.0T
Other languages
Danish (da)
English (en)
Inventor
Nicholas Pomato
Reinhard Bredehorst
Chong-Ho Kim
Richard Mccabe
Carl-Wilhelm Vogel
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23161497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0454783(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of DK0454783T3 publication Critical patent/DK0454783T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DK90902934.0T 1989-01-23 1990-01-23 Sted-specifik in vivo aktivering af terapeutiske lægemidler DK0454783T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30099989A 1989-01-23 1989-01-23

Publications (1)

Publication Number Publication Date
DK0454783T3 true DK0454783T3 (da) 1995-10-16

Family

ID=23161497

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90902934.0T DK0454783T3 (da) 1989-01-23 1990-01-23 Sted-specifik in vivo aktivering af terapeutiske lægemidler

Country Status (12)

Country Link
EP (1) EP0454783B1 (de)
JP (1) JP3273608B2 (de)
KR (1) KR0185967B1 (de)
AT (1) ATE123414T1 (de)
AU (1) AU648015B2 (de)
CA (1) CA2025899A1 (de)
DE (1) DE69019959T2 (de)
DK (1) DK0454783T3 (de)
ES (1) ES2075893T3 (de)
FI (1) FI97692C (de)
NO (1) NO912864L (de)
WO (1) WO1990007929A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
EP1327454A3 (de) * 1989-08-02 2003-12-03 Mitra Medical Technology AB Verfahren zur Behandlung mit Arzneimitteln
US6610299B1 (en) 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
EP0505357B1 (de) * 1989-12-11 1999-03-10 Immunomedics, Inc. Verfahren zum aufspüren von diagnostischen oder therapeutischen mitteln durch antikörper
SE9100142L (sv) 1991-01-17 1992-07-18 Bengt Sandberg En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
AU4663493A (en) * 1992-07-06 1994-01-31 Hybritech Incorporated Method for delivery of cytotoxic agents and components thereof
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
AU701916B2 (en) * 1994-12-23 1999-02-11 London Biotechnology Limited Chemical compounds
EP0844885A2 (de) 1995-08-16 1998-06-03 Zeneca Limited Chemische verbindungen
EP0795334B1 (de) * 1996-03-12 2006-02-01 Sanofi-Aventis Deutschland GmbH Neuartige Prodrugs für die Therapie von Tumoren und entzündlichen Erkrankungen
PL229108B1 (pl) * 2014-08-22 2018-06-29 Celther Polska Spolka Z Ograniczona Odpowiedzialnoscia Sposób wydzielania i oczyszczania estrów chityny (mono-, di‑podstawionych) oraz kopoliestrów chityny z mieszanin poreakcyjnych

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067774A (en) * 1971-05-14 1978-01-10 Syva Company Compounds for enzyme amplification assay
LU85581A1 (fr) * 1984-10-10 1986-06-11 Smb Lab Ensembles d'anticorps monoclonaux diriges contre la lactoferrine humaine et le lysozyme humain
JPS62138496A (ja) * 1985-12-11 1987-06-22 Ihara Chem Ind Co Ltd キチンオリゴマ−の製造方法
AU618209B2 (en) * 1987-07-02 1991-12-12 Akzo N.V. Antigen recognized by mca 16-88
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
ZA893284B (en) * 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies

Also Published As

Publication number Publication date
EP0454783B1 (de) 1995-06-07
FI97692C (fi) 1997-02-10
CA2025899A1 (en) 1990-07-24
KR0185967B1 (ko) 1999-05-01
EP0454783A4 (en) 1992-01-15
NO912864D0 (no) 1991-07-22
ES2075893T3 (es) 1995-10-16
JP3273608B2 (ja) 2002-04-08
NO912864L (no) 1991-09-19
AU5039790A (en) 1990-08-13
WO1990007929A1 (en) 1990-07-26
DE69019959D1 (de) 1995-07-13
FI913511A0 (fi) 1991-07-22
FI97692B (fi) 1996-10-31
EP0454783A1 (de) 1991-11-06
ATE123414T1 (de) 1995-06-15
JPH04503068A (ja) 1992-06-04
AU648015B2 (en) 1994-04-14
DE69019959T2 (de) 1995-10-05
KR910700072A (ko) 1991-03-13

Similar Documents

Publication Publication Date Title
DK0454783T3 (da) Sted-specifik in vivo aktivering af terapeutiske lægemidler
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
NO20034684D0 (no) Innretning for administrering av midler gjennom stratum corcum
DE3277453D1 (en) Use of eucalyptol for enhancing skin permeation of bioaffecting agents
DE69232263D1 (de) Radikalfänger ("spin traps") zur behandlung von mit oxidation von lipiden und proteinen verbundenen erkrankungen
DE60026538D1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
ES2177084T3 (es) Uso de derivados de benzohidrilo sulfinilo para tratar la somnolencia de origen medicamentoso.
BRPI0011856B8 (pt) agonistas de receptor a2a de n-pirazol
BR0109446A (pt) Medicamento para a aplicação intracorpórea, uso de um xanteno halogenado, composição farmacêutica, e, método de tratamento
DE69435318D1 (de) Therapeutische inhibitoren der zellen der glatten gefässmuskulatur
DK164441C (da) Anvendelse af et piperidinderivat til fremstilling af et farmaceutisk praeparat til behandling af smertetilstande
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
ATE173627T1 (de) Medizinische zusammensetzung
HK1046242A1 (en) Preparations for the application of anti-inflammatory agents.
DE69835461D1 (de) Anti-arrhythmische Zusammensetzungen und Behandlungsverfahren
Newell Pharmacokinetically guided dose escalation in phase I clinical trials: Commentary and proposed guidelines.
GR3032224T3 (en) Therapeutic agent for threatened abortion.
AU5643299A (en) Humic acid and its use in the treatment of various conditions
ATE106732T1 (de) Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
WO2001007029A3 (en) Substituted guanidines and the use thereof
Bredehorst et al. Site specific in vivo activation of therapeutic drugs
FR2700543B1 (fr) Sels de dérivés de 4-pyrimidinone, leur préparation et leur application en thérapeutique.
GB2019720A (en) S-adenosyl-L-homocysteine and salts thereof for use in therapy
DK452788D0 (da) Smertestillende praeparat
KR890001555A (ko) 요산 배설용 조성물